Literature DB >> 8621954

Luminometry: a novel bioluminescent immunoassay enhances the quantitation of mucosal and systemic antibody responses.

R J Jackson1, K Fujihashi, H Kiyono, J R McGhee.   

Abstract

We have directly compared enzyme-linked immunoassays (ELISAs) with bioluminescent immunoassays employing derivatives of the bioluminescent molecule aequorin, and have shown that detection of mucosal and serum antibodies is considerably more sensitive when detected by luminometry. Luminometry is based upon counting photons of light via phototubes and is generally similar to scintillation spectrometry. Current commercial luminometric technology employs a phototube which is most efficient for light emission in the 400-420 nm wavelength range. For this reason, we have chosen the bioluminescent molecule, aequorin, which upon the addition of Ca2+ undergoes a conformational change resulting in the emission of blue light at 469 nm. The high quantum yield is reflected by the fact that addition of Ca2+ to 1 ng of recombinant streptaequorin, a covalent conjugate of streptavidin and aequorin, resulted in the production of 7 x 10(8) relative light units. In this study, we show the superior sensitivity of biotin-streptaequorin when directly compared with biotin-streptavidin linked horseradish peroxidase commonly used for ELISA. For example, mice orally immunized once with cholera toxin (CT) did not exhibit detectable fecal IgA antibodies as determined by ELISA, whereas use of streptaequorin and the bioluminescent immunoassay revealed fecal IgA anti-CT-B subunit antibody titers of 1:24 500. In addition, no detectable anti-CT-B antibodies were noted in saliva samples by ELISA 7 days following oral immunization with CT, while IgA endpoint titers could be extrapolated to 1:393 000. The 21 day fecal IgA anti-CT-B titers were 1:512 by ELISA, whereas titers determined by luminometry reached 1:10(7) when Neutralite avidin and biotinylated aequorin were employed. In general, the bioluminescent immunoassay was > 10(4)-fold more sensitive when compared with ELISA for detection of mucosal and serum antigen- and isotype-specific antibody responses. Thus, the bioluminescent immunoassay is a more sensitive assay for detection of antibodies in dilute external secretions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8621954     DOI: 10.1016/0022-1759(95)00276-6

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

1.  Correlations between antibody immune responses at different mucosal effector sites are controlled by antigen type and dosage.

Authors:  D Externest; B Meckelein; M A Schmidt; A Frey
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

2.  Systemically derived large intestinal CD4(+) Th2 cells play a central role in STAT6-mediated allergic diarrhea.

Authors:  M N Kweon; M Yamamoto; M Kajiki; I Takahashi; H Kiyono
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

Review 3.  A systematic review of the biomarker S100B: implications for sport-related concussion management.

Authors:  Stefanie Schulte; Leslie W Podlog; J Jordan Hamson-Utley; Frederick G Strathmann; Heiko K Strüder
Journal:  J Athl Train       Date:  2014 Nov-Dec       Impact factor: 2.860

4.  Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection.

Authors:  M Yamamoto; L S McDaniel; K Kawabata; D E Briles; R J Jackson; J R McGhee; H Kiyono
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

5.  Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses.

Authors:  M Ugozzoli; D T O'Hagan; G S Ott
Journal:  Immunology       Date:  1998-04       Impact factor: 7.397

Review 6.  Ca2+-regulated photoproteins: effective immunoassay reporters.

Authors:  Ludmila A Frank
Journal:  Sensors (Basel)       Date:  2010-12-10       Impact factor: 3.576

7.  Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity.

Authors:  S Yamamoto; Y Takeda; M Yamamoto; H Kurazono; K Imaoka; M Yamamoto; K Fujihashi; M Noda; H Kiyono; J R McGhee
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.